No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Jasper Therapeutics, Maintains $65 Price Target
Jasper Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 202.33% HC Wainwright & Co. → $65 Reiterates Buy → Buy 05/06/2024 202.33% HC Wainwright & Co. →
RBC Capital Sticks to Their Buy Rating for Jasper Therapeutics (JSPR)
Buy Rating on Jasper Therapeutics: High Hopes for Briquilimab's Clinical Trials
10-Q: Quarterly report
Analysts Are Bullish on Top Healthcare Stocks: Stereotaxis (STXS), Jasper Therapeutics (JSPR)